Please login to the form below

Not currently logged in
Email:
Password:

IFPMA appoints director general

Thomas Cueni brings expertise from Interpharma and EFPIA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has selected Thomas Cueni as its new director general.

Cueni takes on responsibility for representing the interests of the research-based pharma industry at a global level, working with organisations and governments to promote the value of pharmaceutical innovation and improve access to treatments.

He brings considerable experience as secretary general of Interpharma, the Basel-based association representing Swiss pharma firms, during which time he had been closely associated with IFPMA as a member of its council.

Cueni also brings industry expertise from the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he served in a policy-shaping and advocacy capacity.

Ian Read, IFPMA's president and chief executive and chairman of Pfizer, said: “Thomas has extensive experience in the research-based biopharmaceutical industry and a deep understanding of what is needed to support the continued discovery and development of important life-saving and life-enhancing medicines and vaccines.

“I look forward to working closely with Thomas in advocating for sustainable health policies that foster innovation and ensure patient access to these important advances.”

8th February 2017

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...